Innocoll is an international, specialty pharmaceutical and drug delivery company engaged in the research, development and manufacture of innovative collagen based medical products ulilizing the company's drug delivery technology platforms (CollaRx®and LiquiColl®). These technologies are fully biodegradable and designed for the localized, site-specific delivery of a wide variety of drugs and are specifically intended to minimize systemic exposure and associated side effects.

Localized delivery provides a way of targeting the optimum dose of a drug to precisely where it is needed, rather than distributing excessive and sometimes unnecessary concentrations throughout the body via the systemic circulation. Such delivery systems can enhance a drug's efficacy and reduce unwanted side effects compared to oral or intravenous administration, particularly when targeting poorly vascularized areas such as bone and chronically infected wounds. Localized delivery can also be used as an adjunct to systemic therapy, such as in the prevention of infection or management of pain.

The parent company, Innocoll Inc., has three operating divisions:

• Drug Delivery and R&D Division (Innocoll Technologies)

• Sales and Marketing Division (Innocoll Pharmaceuticals)

• Commercial Manufacturing Division (Syntacoll)

Innocoll Technologies is responsible for the development of new products based upon the proprietary CollaRx and Liquicoll technologies as well as research into new collagen-based pharmaceutical products and medical devices. Internal programs are focussed on treatment and prevention of surgical site infections, advanced wound care, post-operative pain management, prevention of surgical adhesions and oncology. We are also seeking co-development partnerships with pharmaceutical and biotechnology companies interested in using our technologies to develop first-line products or localized delivery line extensions of existing brands.

Innocoll Pharmaceuticals is responsible for establishing and overseeing collabrations with Innocoll's marketing partners. The lead marketed product, Gentamicin Surgical Implant (Collatamp G), is a leave-behind surgical implant indicated for the treatment and prevention of post operative infections. The product is promoted to surgeons across a broad range of surgical specialities, including orthopedic, thoracic, abdominal, and vascular procedures, where there is often increased risk of post-operative infection or where such infections can lead to severe complications. It is currently marketed in more than 30 territories under various trade names throughout most of Europe and other "rest-of-world" countries in Latin America, Middle East, Asia and Africa. Innocoll is also developing Collatamp G for the US market where it is currently in Phase 3 clinical trials for the prevention of surgical site infections and Phase 2 trials as a topical treatment for infected diabetic foot ulcers.

Syntacoll AG (Switzerland) is the holding company for Innocoll's two commercial manufacturing facilities, Syntacoll GmbH in Saal, Germany, and Syntacoll Pty in Midrand, South Africa. An additional manufacturing facility is planned at Innocoll Technologies HQ in Roscommon, Ireland.

Out-license of internal pipeline products for the prevention of surgical site infections, treatment and prevention of infected diabetic foot ulcers, advanced wound care, prevention of surgical adhesions and oncology. Partnerships with pharmaceutical and biotechnology companies interested in localized drug delivery of their proprietary molecules.

More press releases